Efficacy of Co- enzyme Q-10 in pneumonia

Efficacy of Co- enzyme Q-10(Ubiquinone) in geriatrics community-acquired pneumonia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201305159855N3

Enrollment

150

Registered

2013-06-02

Start date

2013-05-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: community acqured pnemonia. Condition 2: community acqured pnemonia. Condition 3: community acqured pnemonia. Pneumonia due to Streptococcus pneumoniae Pneumonia due to Haemophilus influenzae Bacterial pneumonia, not elsewhere classified

Interventions

Intervention 1: Iintervention group :Standard traetment of pneumonia (Ceftriaxon + Azithromycin ) + Coenzyme Q 100mg BID for 14 days. Intervention 2: Control group : Standard treatment of pneumonia(ce

Treatment - Drugs

Placebo

Iintervention group :Standard traetment of pneumonia (Ceftriaxon + Azithromycin ) + Coenzyme Q 100mg BID for 14 days

Control group : Standard treatment of pneumonia(ceftriaxon + Azythromycin)+ placebo

Eligibility

Sex/Gender

All

Age

65 Years to 99 Years

Inclusion criteria

Inclusion criteria: inclusion criteria : age=65; Community acquired pneumonia patients exclusin criteria : the age of less than 65 years ; hemodynamic instability ; chronic liver failure; chronic heart failure; chronic renal failure ; Co- enzyme Q-10 consumption during 1 month before arrival to study; history of allergic reactions; receiving the drugs or compounds with antioxidant effect such as vitamin C; vitamin E or vitamin A; HIV patients

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Clinical Signs and Symptoms(Temprature,Respiratory rate,Pulse rate,Blood pressure,Dyspnea,Sputum production,Crackle and rale). Timepoint: 0,3,7,14. Method of measurement: Physical examination based on quastionair.	—

Secondary

Measure	Time frame
Decrease of leukocyte count. Timepoint: 0,3,7,14. Method of measurement: Complet blood count.;Decrease of CRP and ESR. Timepoint: 0,3,7,14. Method of measurement: Check of ESR and CRP.;Blood O2 Saturation. Timepoint: 0,3,7,14. Method of measurement: Check of blood O2.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGhazaleh Akbarifard

Arak University of Medical Sciences

gakbarifard@yahoo.com+98 86 1417 3645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026